Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of intravitreal triamcinolone + photodynamic therapy versus intravitreal bevacizumab + photodynamic therapy versus intravitreal bevacizumab for retinal angiomatous proliferation
2008-001468-34Phase 3Active
- Sponsor
- Luigi Sacco University Hospital
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab and triamcinolone in Subretinal neovascularization (3 arms), sponsored by Luigi Sacco University Hospital. Primary endpoint: Stabilization of lesion size. Started Mar 2009; status: active.
02
Drugs
bevacizumabtriamcinolone
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2008-001468-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001468-34.